Capricor Therapeutics shares tumble after FDA reviewers raise concerns over Duchenne therapy Proactive Investors (US) 21h
The peptide gray market is already here. The FDA is just catching up. Reason 15h Pharma US Politics All sources
Capricor Therapeutics shares tumble after FDA reviewers raise concerns over Duchenne therapy Proactive Investors (US) 21h Duchenne Capricor Therapeutics Heart Disease All sources
Outlook Therapeutics wins FDA approval for Lytenava in wet AMD Pharmaceutical Technology 1d Pharma All sources
